| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash used in operating activities | -9,732,174 | -8,601,571 |
| Purchase of in-process research and development assets | 515,996 | - |
| Net cash used in investing activities | -515,996 | - |
| Proceeds from the exercise of stock options | 38,274 | 19,137 |
| Net cash provided by financing activities | 38,274 | 19,137 |
| Net decrease in cash and cash equivalents | -10,209,896 | -8,582,434 |
| Cash and cash equivalents at beginning of period | 38,339,762 | - |
| Cash and cash equivalents at end of period | 28,129,866 | - |
Coya Therapeutics, Inc. (COYA)
Coya Therapeutics, Inc. (COYA)